A Rice University student decided to use his data science skills for good. Photo courtesy of Biokind Analytics

For Alex Han, it all started with peanut butter.

Han was a high school student in Korea when he learned that the spread is a pure odorant that could be used to test smell in each hemisphere of the brain—issues on the left side was thought to be a predictor for Alzheimer’s disease. He later learned that the method wasn’t as airtight as previously thought, but Han was hooked. Alzheimer’s research became the teenager’s passion. While still in high school, Han began volunteering for Alzheimer’s Los Angeles, translating their brochures into Korean.

When it came time to choose a college, Han says Rice University appealed to him for many reasons.

“I loved the atmosphere. I loved the campus—it’s so beautiful. The diverse food, the people, I even liked the highway,” he says of Houston. “In Korea, everything is so close and compact. I loved the whole scenario of the city.”

A scholarship was also part of the appeal, as well as the pull of the world’s largest medical center. Han’s instincts were correct. Now, a junior at Rice, he has been working at renowned geneticist Huda Zoghbi’s Baylor College of Medicine lab for almost two years.

But dividing his obligations between full-time studies and his wet lab position wasn’t enough to keep Han’s active mind occupied. Last May, the statistics and biochemistry student began another endeavor that uses both his specialties. It was then that he founded Biokind Analytics. The nonprofit was designed to explore how data science can support health care nonprofits.

Han reached out to Alzheimer’s Los Angeles to offer his data analysis services on a volunteer basis and was shocked that the association had never considered it before.

“I was really surprised—even small stores and restaurants use statistics to boost their profits. [Alzheimer’s Los Angeles] receive a couple million dollars every year in donations. They have data stores but hadn’t really capitalized yet in the area of analytics.”

Han, along with a small team of Rice students, including vice president Zac Andrews and development director Masha Zaitsev, made Alzheimer’s Los Angeles a pet project, analyzing geospatial trends in its donorship and interpreting the past year’s donation trends. “We wanted to see if the demand was the same in Houston. We found that this pattern was consistent. A lot of nonprofits are willing to have us analyze the data sets they’ve already been tracking and provide data analysis for healthcare nonprofits.”

Less than a year after Han established Biokind Analytics, the 501(c)(3) already has seven chapters on college campuses around the country. From UC Davis and San Diego in the West to Brown University and the University of Virginia on the East Coast, the data science students have helped a diverse range of medical nonprofits, mostly based in the Houston area. They run the gamut from ALS Association of Texas to Nora’s Home, which serves organ failure and transplant patients.

Biokind Analytics has now completed seven projects and analyzed $100 million in funds. Each student group includes four to six members, mostly majors in the worlds of statistics, data science, and biochemistry, all working with the help of faculty advisors. At a total of about 35 students nationwide, Han says that he’s dedicated to growing at a steady pace to avoid potentially expanding too fast, too soon.

Another question for the future is what will happen to Biokind Analytics when Han completes his undergraduate studies in 2024. He plans to continue his medical studies with the goal of one day becoming a physician specializing in Alzheimer’s who uses data analytics to aid in patient care. But no matter how active Han continues to be in the nonprofit he started, his stated attachment to the cause and a growing group of both student leaders and healthcare associations eager for their services are sure to keep Biokind Analytics active long after graduation.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston cleantech, space startups named to World Economic Forum cohort

top honor

Two Houston-based startups have been selected to join the World Economic Forum's Technology Pioneers community.

The two-year program aims to help mission-driven, early-stage start-ups scale their innovations through multi-stakeholder initiatives, co-creating partnerships and other gatherings for community members. One-hundred startups are selected each year from around the globe, this year hailing from 23 countries and working in AI, energy, space, biotech markets and more.

Cleantech startup Vaulted Deep was one of 11 energy and climate companies to be named to the cohort. Julia Reichelstein and Omar Abou-Sayed founded the company in 2023. Its technology injects excess organic waste underground to remove carbon dioxide from the atmosphere.

Last year, Vaulted Deep inked a 12-year deal with Microsoft to remove up to 4.9 million metric tons of carbon dioxide from the environment.

The startup has earned several accolades in recent years, including a No. 3 spot on Fast Company’s list of the World’s Most Innovative Companies of 2026. It was also recently named to market intelligence and advisory firm Cleantech Group's annual Global Cleantech 100 list for a second year in a row.

"Waste management is one of the world's great invisible infrastructure systems ... The need for new infrastructure is growing as disposal challenges become more complex and regulations evolve. Vaulted is building the first new disposal pathway for organic waste in decades by putting it deep underground, permanently," the company shared in a LinkedIn post. "This year, we're joining the World Economic Forum's 2026 Tech Pioneers alongside innovators working on the many interconnected challenges shaping our future."

Houston-based Venus Aerospace was also selected to join the cohort, along with six other spacetech companies. The company was founded in 2020 by Sassie and Andrew Duggleby.

The startup specializes in next-generation rocket engine propulsion as a cleaner alternative to traditional combustion engines. The company's rotating detonation rocket engine (RDRE) burns fuel more efficiently and completed a successful high-thrust test flight last year. Venus says it’s the only company in the world that makes a flight-proven, high-thrust RDRE with a “clear path to scaled production.”

"Frontier technologies matter most when they expand what people, industries, and nations can do," Sassie Duggleby, co-founder and CEO of Venus, said in a news release. "For Venus, RDRE does not just represent a more efficient engine. It is a foundation for faster movement, more capable space systems, and new forms of connectivity across the planet. Being named a Technology Pioneer validates the potential of this technology to help shape a future where distance is less limiting."

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston Methodist receives record $110M gift, names future tower

historic gift

Houston Methodist has received the largest gift in the health system's history to establish new funds for neurological, neuroscience, and women’s health research and treatment.

The $110 million gift comes from Houston-based The Brockman Medical Research Foundation, which supports education and research in the science, medicine and healthcare fields. In response, Houston Methodist announced that it will name its forthcoming 26-story hospital facility the Brockman Centennial Tower.

The tower’s entrance will be named the Anna Margaret Bellows Centennial Hall to honor Anna Margaret Bellows, a young camper who died during the Camp Mystic flooding last summer.

“This extraordinary gift accelerates discovery and transforms how care is delivered,” Dr. Marc Boom, president and CEO of Houston Methodist, said in a news release. “We are grateful to The Brockman Medical Research Foundation for its incredible generosity and vision that will help change the lives of generations of patients. Naming Centennial Tower in recognition of this gift reflects the scale of this commitment and its impact on the future of neuroscience, neurological care and women’s health.”

The gift will be divided into two parts:

  • $100 million will go toward creating an innovation fund within the Houston Methodist Academic Institute and the Houston Methodist Neurological Institute
  • $10 million will be devoted to Houston Methodist's Department of Obstetrics and Gynecology

“This tremendous gift will accelerate translational research that broadens our understanding of neurological and other diseases,” Dr. Jenny Chang, president and CEO of the Houston Methodist Academic Institute, added in the release. “It will allow us to leverage state-of-the-art platforms to detect, diagnose and deliver therapeutics, keeping patient care at the center of our mission.”

The Brockman Centennial Tower is expected to open next year in the Texas Medical Center. Spanning more than 1 million square feet, it will house 400 patient beds, an expanded emergency department, new operating rooms and a rooftop garden. It will be connected to Houston Methodist's flagship Paula and Joseph C. “Rusty” Walter III Tower, which opened in 2018. The Centennial Tower was estimated to cost $1.4 billion when announced in 2022.

In addition to the news of the Brockman gift, Houston Methodist also announced this month that it has launched the Houston Methodist Center for Cell and Gene Therapy and tapped an internationally recognized scientist as its leader.

The new center is focused on discovering and developing innovative and cost-effective therapies for a variety of congenital and acquired diseases, including cancer, HIV and cardiovascular disease.

Dr. Malcolm Brenner has been named as the center's inaugural leader and will assume the role starting in October. He will work alongside scientists and support staff from Baylor College of Medicine and Texas Children's Hospital.

Brenner is a professor of pediatrics, medicine, molecular and human genetics and translational biology at Baylor College of Medicine. He is known for making early advances in using bone marrow transplantation as a form of cell therapy and in engineered immune-cell treatments for cancer and infections, according to a release from Houston Methodist.

“Malcolm Brenner is a pioneer in the field of cell and gene therapy and is uniquely qualified to lead Houston Methodist’s research efforts in this field,” Chang added. “His vision and leadership will play a pivotal role in advancing our work in this space.”